Tandem Diabetes Care (TNDM) Operating Leases (2019 - 2026)

Tandem Diabetes Care has reported Operating Leases for 8 years, with the latest figure at $112.9 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 21.5% year-over-year to $112.9 million; the trailing twelve-month figure through Mar 2026 stood at $112.9 million (down 21.5% YoY), and the FY2025 full-year result was $115.0 million, up 8.03% from the prior year.
• Operating Leases for Q1 2026 stood at $112.9 million, down from $115.0 million in the prior quarter.
• The five-year high for Operating Leases was $143.8 million in Q1 2025, with the low at $3.0 million in Q2 2022.
• Historically, Operating Leases has averaged $113.4 million across 5 years, with a median of $118.4 million in 2025.
• Annual changes were most pronounced in 2022 — Operating Leases plunged 91.81% — and 2023, when it soared 3846.67%.
• Tandem Diabetes Care's Operating Leases stood at $123.5 million in 2022, then slipped by 8.06% to $113.6 million in 2023, then decreased by 6.3% to $106.4 million in 2024, then grew by 8.03% to $115.0 million in 2025, then retreated by 1.83% to $112.9 million in 2026.
• The last three Operating Leases figures came in at $112.9 million (Q1 2026), $115.0 million (Q4 2025), and $118.4 million (Q3 2025), per Business Quant data.